Cargando…
Tafolecimab, A Novel Member of PCSK9 Monoclonal Antibodies, Is Worth Expecting in a Chinese Population
[Figure: see text]
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Elsevier
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10442878/ https://www.ncbi.nlm.nih.gov/pubmed/37614538 http://dx.doi.org/10.1016/j.jacasi.2023.06.002 |